Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Massachusetts sues Publicis over ties to Purdue Pharma, opioids

Published 05/06/2021, 01:53 PM
Updated 05/06/2021, 02:56 PM
© Reuters. FILE PHOTO: The logo of Publicis group is seen at the high profile startups and high tech leaders gathering, Viva Tech,in Paris, France May 16, 2019. REUTERS/Charles Platiau

© Reuters. FILE PHOTO: The logo of Publicis group is seen at the high profile startups and high tech leaders gathering, Viva Tech,in Paris, France May 16, 2019. REUTERS/Charles Platiau

By Jonathan Stempel

(Reuters) -Massachusetts sued a unit of French advertising company Publicis Groupe SA (PA:PUBP) on Thursday, accusing it of fueling the U.S. opioid crisis by using unfair and deceptive marketing to help drugmaker Purdue Pharma sell more OxyContin.

The state attorney general Maura Healey said Publicis Health created a public nuisance from 2010 to 2019 through its work for drugmakers on campaigns to persuade doctors to prescribe more opioids, including to patients who did not need them.

Purdue alone paid Publicis more than $50 million for its work, which continued even after Publicis proposed in 2016 that Purdue shut down its sales force to "fully embrace a deeper-held responsibility" the drugmaker owed the public, Healey said.

"They knew what they were doing was wrong, they made the opioid crisis worse, and they kept cashing Purdue's checks," Healey told reporters in a Zoom meeting. "What they did was wrong. It hurt people. It killed people."

A Publicis Health spokesman said there was no legal basis for the lawsuit, and that the statute of limitations had run out. He also said the company's work was "completely lawful," and limited to implementing Purdue's advertising plan and buying ad space.

The advertising agencies Leo Burnett and Saatchi & Saatchi are among Publicis' other businesses.

Healey's lawsuit filed in a state court in Boston seeks civil penalties and restitution to victims.

It followed agreements this year by the consulting firm McKinsey & Co to pay $641 million to resolve lawsuits by all 50 U.S. states, Washington, D.C., and five U.S. territories over its role in the opioid epidemic.

© Reuters. FILE PHOTO: The logo of Publicis group is seen at the high profile startups and high tech leaders gathering, Viva Tech,in Paris, France May 16, 2019. REUTERS/Charles Platiau

The U.S. Centers for Disease Control and Prevention has said nearly 500,000 people died from opioid overdoses from 1999 to 2019.

Purdue is operating in bankruptcy. In March, it proposed a restructuring plan that would steer profits to opioid victims, and require members of the Sackler family who own the company to contribute nearly $4.3 billion.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.